在超越IC50-A的计算动态模型中,在酶抑制治疗中,药物耐药性
J Roadnight Sheehan1, Astrid S de Wijn1, Thales Souza Freire2
1Department of Mechanical and Industrial Engineering, Norwegian University of Science and Technology, Trondheim, Norway.
这项研究挑战了使用折叠IC50值来选择癌症疗法. 一个新的指标"抑制性减少能力"更好地预测慢性髓性白血病 (CML) 治疗中的耐药性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 治疗耐药性是治疗癌症和传染病的一个重大挑战.
- 药物选择通常以IC50或折叠-IC50值为指导,特别是在耐药性情况下.
- 慢性髓性白血病 (CML) 作为向治疗和耐药性的模型,大约25%的患者对一线治疗产生耐药性.
研究的目的:
- 评估使用折叠-IC50值来指导耐药CML药物选择的疗效.
- 开发和应用一个预测模型来评估Abl1抑制剂对抗抗性Abl1酶突变的有效性.
- 提出一种用于选择治疗的新参数,以提高治疗疗效和患者的治疗结果.
主要方法:
- 开发一个结合催化,抑制和药物动力学数据的计算模型.
- 应用该模型来模拟三种Abl1抑制剂对各种Abl1酶突变体的影响.
- 对比"抑制性减少能力"的预测能力与传统指标,如折叠-IC50.
主要成果:
- 这项研究表明",抑制性减少能力"是药物耐药性的更有效指标,而不是折叠IC50值.
- 分析表明,指导治疗选择的现有方法可能对抗性突变来说不是最佳的.
- 该模型提供了对不同突变抑制剂组合的复杂抵抗机制的见解.
结论:
- 折叠IC50值不足以指导耐药CML的药物选择.
- "抑制性减少能力"为预测治疗反应和选择有效的Abl1抑制剂提供了优越的指标.
- 拟议的新参数有可能提高治疗效率并改善针对性癌症治疗中的患者结果.
更多相关视频
10:28A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors
Published on: August 17, 2019
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
相关概念视频
Nonlinear Pharmacokinetics: Michaelis-Menten Equation
Vmax represents the maximum achievable process rate, while KM, known as the Michaelis constant, signifies the drug concentration at which the process rate reaches half its maximum. This relationship between Vmax, KM, and Cp gives rise to three distinct...
Time Course of Drug Effect
Treatment Resistant Cancers
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Determination of Michaelis Constant and Maximum Elimination Rate
These parameters can be estimated by analyzing plasma concentration data post-drug administration. A notable example of this application is phenytoin, a drug with capacity-limited kinetics. It's recommended that phenytoin should be administered at two...
Quantitative Aspects of Drug-Receptor Interaction
